[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Basel, Switzerland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":689},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,175,0,25,[9,43,68,98,127,156,190,216,248,275,302,328,363,389,416,435,455,476,509,535,561,596,623,647,666],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100646692","phase-3-efficacy-of-non-opioid-drugs-in-addition-to-opioid-therapy-for-cancer-pain-management-100646692",false,"NCT07682558","Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management","Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management: a Double-blind, Randomized, Three Arm, Placebo Controlled Trial Assessing the Key Non-opioids Dipyrone (Metamizole) and Ibuprofen","NoDoubt","Inclusion Criteria:\n\n* Inpatient setting (discharge possible, if patient returns for End of Study Visit)\n* Diagnosis of metastatic or locally advanced cancer\n* Cancer pain as defined by IASP (International Association for the Study of Pain)\n* Cancer pain therapy with opioids indicated for pain management or start thereof at baseline (drug, dose, and route at treating physician's discretion)\n* Average daily pain intensity ≥ 3 on NRS (Numeric Rating Scale)\n* Ability to swallow oral medication\n* Informed Consent as documented by signature\n\nExclusion Criteria:\n\n* History of allergy or allergy-like symptoms (bronchospasm, urticaria or severe cutaneous adverse reactions (SCARs)) or hypersensitivity to dipyrone (or other pyrazolones or pyrazolidines) or ibuprofen (or other Non-steroidal anti-inflammatory drug incl. acetylsalicylic acid)\n* Moderate to severe renal insufficiency (creatinine-eGFR (estimated Glomerular Filtration Rate) \\\u003C45 ml\u002Fmin)\n* Severe heart failure (New York Heart Association class III-IV)\n* Severe hepatic impairment (liver cirrhosis with ascites) or hepatic porphyria\n* History of agranulocytosis induced by dipyrone (or other pyrazolones or pyrazolidines)\n* Active gastric and\u002For duodenal ulcers or bleeding\n* History of recurrent gastric and\u002For duodenal ulcers or gastrointestinal bleeding (≥2 distinct episodes of proven ulceration or bleeding) or increased tendency to bleeding\n* Third trimester of pregnancy\n* Breastfeeding\n* G6PD deficiency\n* Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)\n* Intrathecal or epidural opioids or local or regional anesthetic therapy\n* Additional second opioid for co-analgesic effects or other reasons (e.g., methadone, buprenorphine)\n* Initiation of therapy with transdermal therapeutic system (TTS) opioid \\\u003C48 hours before start of IMP\n* Use of non-opioids with long half-life (i.e., acemetacin, celecoxib, etodolac, etoricoxib, ketorolac, naproxen, piroxicam, tenoxicam)\n* Pain unrelated to cancer (e.g. chronic non-cancer pain \\[CNCP\\], postoperative, particularly following coronary artery or cardiopulmonary bypass surgery)\n* Inability to follow study procedures or adhere to protocol (e.g., due to language problems, psychological disorders, dementia)\n* Inability to abstain from other non-opioids (apart from IMP (Investigational Medicinal Product)) during study participation\n* Participation in any interventional study targeted at pain management\n* Participant is a family member or employee of the investigator","ALL","18 Years",{"count":21,"type":22},318,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The investigators investigate the efficacy of non-opioid analgesics compared to placebo together with opioid therapy for cancer pain management.",[28,29],"Cancer Pain","Cancer Palliative Care","NOT_YET_RECRUITING","2026-08-18",{"date":33,"type":34},"2026-08-19","ACTUAL",{"date":36,"type":22},"2026-10",{"date":38,"type":22},"2029-11",{"name":40,"class":41},"University Hospital, Basel, Switzerland","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":7},"100652747","severe-complications-during-ventricular-tachycardia-or-premature-ventricular-complex-ablation-100652747","NCT07777744","Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation","Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation - an International Multicenter Collaborative Study Group","Inclusion Criteria:\n\n* Centers : Centers participating in the present collaborative study group. Invitation to participate will be based either upon personal referral of one of the investigator, previous collaboration or based on a meta-analytic review of the literature published on the subject within the past 20 years.\n* Patients: Females and males of \\>18 years undergoing any type of VT\u002FPVC ablation. While we will accept redo-procedure we will ask for a unique patient-identifier to link procedures belonging to the same patients together.\n* Interventions: VT\u002FPVC ablation (first intervention or re-do) as routinely performed by the participating centers\n* Outcomes: Severe complications, defined as hemodynamic instability requiring mechanical intensive-care management, tamponade, stroke, cardiac arrest, myocardial infarction, phrenic nerve palsies, major bleeding requiring transfusion, vascular or cardiac complication requiring surgery, procedure-related death.\n* Setting: Observational cohort studies, registries, retrospective cohort studies. Data stemming from RCTs (Randomized controlled trials) will not be collected as they likely do not represent a \"real-life\" setting.\n* Length of follow-up: Peri-procedural complications\n* Years considered: Not limited to a specific time-frame, but to reflect common ablation practices, we will focus on data from the 20 past years.\n* Number of patients provided : No lower limit of patients provided per dataset or ablation volume per year to include high- as well as low-volume centers\n\nExclusion Criteria:\n\n* Refusal of the center to participate.\n* Less than 10 procedures available in the dataset (no case reports)\n* Missing essential baseline characteristics, missing collection of sufficient details regarding each complication.",{"count":51,"type":22},15000,"OBSERVATIONAL","The investigators aim to characterize patients presenting with a severe ventricular tachycardia (VT) and premature ventricular complex (PVC)-ablation-related complication including patient characteristics, procedural details and subsequent management of the complication by gathering existing patient-level data.",[55,56],"Ventricular Tachycardia (VT)","Premature Ventricular Complexes",[58],"Ablation","RECRUITING","2026-08-17",{"date":62,"type":34},"2026-08-20",{"date":64,"type":34},"2024-07-01",{"date":66,"type":22},"2028-12-31",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":88,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":42},"100648630","micro-choice-based-intervention-for-multicausal-fatigue-100648630","NCT07726082","Micro-choice-based Intervention for Multicausal Fatigue","Micro-choice-based Intervention for Multicausal Fatigue: Proof of Concept Study","CHOOSE-POC","Inclusion Criteria:\n\n\\- Experiencing persistent fatigue with a significant impact on daily functioning (Chalder Fatigue- Scale bimodal ≥ 4)\n\nExclusion Criteria:\n\n* Have insufficient proficiency in German to complete study-related questionnaires\n* Lack the cognitive capacity to understand study procedures (e.g. due to dementia)\n* Present with severe medical conditions that may interfere with participation (e.g., advanced organ failure, uncontrolled inflammatory or autoimmune diseases, or severe psychiatric disorders)\n* Have active cancer or are currently undergoing cancer treatment\n* Are deemed incompatible with group participation during the preparation phase, based on a team assessment. Reasons for exclusion based on group incompatibility include:\n\n  1. Need for a level of individual therapeutic support that exceeds what can be provided in a group setting; b) Refusal to engage in group-based therapy; c) Personality traits that are considered incompatible with group dynamics; d) Failure to attend the mandatory preparatory webinar (no-show is considered a no-go); e) Other significant reasons as determined by the therapeutic team)","65 Years",{"count":78,"type":22},24,[80],"NA","This proof-of-concept study aims to evaluate the feasibility, acceptability, and potential benefits of a novel multimodal approach: the micro-choice-based intervention.",[83,84,85,86,87],"Multicausal Fatigue","Fatigue","Post COVID Condition","Long COVID Syndrome","Postviral Fatigue",[89,90],"neuroplastic therapy","group intervention","2026-08-14",{"date":31,"type":34},{"date":94,"type":34},"2026-08-13",{"date":96,"type":22},"2027-08",{"name":40,"class":41},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":106,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":42},"100651648","evaluation-of-an-mri-based-prostate-cancer-screening-program-visioning-5-year-follow-up-round-visioning-iii-100651648","NCT07762911","Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)","Visioning III","Inclusion Criteria:\n\n* \"well-informed men\" with the wish for prostate cancer screening:\n* prostate biopsy naïve\n* life expectancy \\> 10 years\n* Paticipant in the VISIONING study\n\nExclusion Criteria:\n\n* prostate volume \\> 80ml\n* acute urinary tract infection UTI\n* NIH-CPSI score over or equal to19\n* IPSS score over or equal to 20 (leads to initiation of urologic diagnostics and treatment)\n* life expectancy \\\u003C 10 years",true,"MALE","50 Years",{"count":109,"type":22},300,[80],"Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial overdiagnosis and overtreatment of clinically insignificant disease. Biparametric magnetic resonance imaging (bpMRI) has emerged as a promising imaging modality to improve the detection of clinically significant prostate cancer while reducing unnecessary biopsies.\n\nIn this prospective follow-up study, men who previously participated in prostate cancer screening and had no evidence of malignancy at baseline will be invited to undergo repeat screening approximately five years later. The study aims to evaluate the longitudinal performance of repeat screening using PSA and MRI, determine the incidence of newly detected clinically significant prostate cancer after an initial negative screening, and assess changes in imaging and clinical findings over time. The results will provide evidence on the value and optimal interval of repeat prostate cancer screening in men with an initially negative evaluation.",[113],"Prostate Cancer",[115,113,116,117,118,119],"Prostate","Prostate cancer screening","Prostate carcinoma","Prostate-specific antigen (PSA)","MRI-based screening","2026-08-10",{"date":94,"type":34},{"date":123,"type":34},"2026-06-01",{"date":125,"type":22},"2028-06-01",{"name":40,"class":41},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":105,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":42},"100448702","investigation-of-biofilm-formation-on-temporary-push-on-rings-of-implant-crowns-100448702","NCT05122897","Investigation of Biofilm Formation on Temporary push-on Rings of Implant Crowns","Temporary push-on Rings of Antimicrobial Alloys for Transmucosal Implant Abutment Systems: a Randomized Clinical Study on Early and Mature Biofilm Formation","Inclusion Criteria:\n\n* Informed Consent signed by the subject\n* Presence of one or more bone level titanium implant prior to insertion of the final restoration\n* No systemic illness\n* No heavy smoking (smoking \\\u003C10 cigarettes\u002Fday)\n* No pregnancy\n* No active periodontitis (probing pocket depth ≤4 mm)\n* No pharmacological treatment or antibiotic therapy during or up to three months before the study\n\nExclusion Criteria:\n\n* Systemic illness (e.g. Diabetes)\n* Heavy smoking (smoking \\>10 cigarettes\u002Fday)\n* Known or suspected non-compliance, drug or alcohol abuse\n* Pregnancy\n* Active periodontitis (probing pocket depth \\>4 mm)\n* Pharmacological treatment or antibiotic therapy during or up to three months before the study",{"count":135,"type":22},33,[80],"This in-vivo study investigates early (48h), mature (2 weeks) and long-term (3 months) biofilm formation and composition on temporary push-on cones (exchangeable conical rings) made of noble-alloy-based materials (Pagalinor, PA) in comparison to Titanium-6Aluminum-7Niobium alloy (TAN) presently used in the transmucosal portion of dental implant abutments.",[139,140,141],"Dental Plaque","Oral Biofilm","Peri-implantitis",[143,144,145,146,147,148],"Titanium-6Aluminum-7Niobium alloy","Pagalinor","transmucosal implant abutment","implant crowns","temporary push-on rings","Variobase abutments",{"date":150,"type":34},"2026-08-11",{"date":152,"type":34},"2022-01-11",{"date":154,"type":22},"2026-12-31",{"name":40,"class":41},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":173,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":42},"100644472","bridging-the-gap-in-psychosocial-care-for-cancer-survivors-100644472","NCT07672314","Bridging the Gap in Psychosocial Care for Cancer Survivors","Bridging the Gap in Psychosocial Care for Cancer Survivors: Integrating Digital Screening With Navigation Call","BRIDGE","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Under oncological care at the USB for ≥9 months\n* Completion of primary cancer treatment (see definition below)\n* Attendance at routine oncological follow-up at USB\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Primary brain tumors\n* Severe cognitive impairment\n* Acute psychiatric symptoms that may impair the participant's ability to provide informed consent or comply with study procedures\n* Insufficient German language skills",{"count":165,"type":22},50,[80],"The study aims to assess the feasibility and acceptability of the implementation of a routine digital psychosocial screening combined with a psycho-oncological Navigation Call for cancer survivors after completion of primary treatment with the goal to improve identification of psychosocial needs and facilitate access to supportive care.",[169,170,171,172],"Cancer Survivorship","Psychological Distress","Psycho-Oncology","Supportive Care",[174,175,176,177,178,179,180,181,182],"Cancer survivors","Survivorship care","Digital screening","Psycho-oncology","Psychosocial distress","Patient-reported outcomes (PROs)","Navigation Call","Feasibility study","Acceptability","2026-08-07",{"date":120,"type":34},{"date":186,"type":34},"2026-06-26",{"date":188,"type":22},"2028-05",{"name":40,"class":41},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":105,"sex":18,"minAge":19,"maxAge":107,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":42},"100620718","plasma-oxytocin-response-to-oral-estrogens-in-healthy-controls-and-avp-deficiency-100620718","NCT07361263","Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency","Plasma Oxytocin in Response to Oral Estradiol Valerate and Ethinylestradiol in Healthy Controls and Patients With AVP-Deficiency","PHOENIX","Inclusion Criteria:\n\nPart 1\n\n1. Adult healthy controls\n2. No medication (including hormonal contraception)\n3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months\n\nPart 2\n\n1. Confirmed diagnosis of AVP-Deficiency\n2. Age ≥ 18 years\n3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months or in the case of hormone replacement therapy, with a 1-week pause from the respective treatment\n\nExclusion Criteria:\n\nPart 1\n\n1. Participation in a trial with investigational drugs within 30 days\n2. BMI \\>30\n3. Age \\>50\n4. Illicit substance use (except for cannabis) during the last 30 days\n5. Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n6. Tobacco smoking \\>10 cigarettes\u002Fday\n7. Pregnancy and breastfeeding\n8. Hormonal contraception\n9. Migraine with and without aura\n10. Any cardiometabolic, cardiovascular, and hematological diseases (including deep vein thrombosis\u002Fpulmonary embolism and thrombophilia (DVT\u002FPE))\n11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range\n12. Diagnosed chronic kidney disease (CKD) \\> grade III (GRF \\\u003C 30ml\u002Fmin)\n\nPart 2\n\n1. Participation in a trial with investigational drugs within 30 days\n2. BMI \\>30\n3. Age \\>50\n4. Illicit substance use (except for cannabis) during the last 30 days\n5. Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n6. Tobacco smoking \\>10 cigarettes\u002Fday\n7. Pregnancy and breastfeeding\n8. Hormonal contraception\n9. Migraine with and without aura\n10. Any cardiometabolic, cardiovascular, and hematological diseases (including DVT\u002FPE and Thrombophilia)\n11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range\n12. Diagnosed CKD \\> grade III (GRF \\\u003C 30ml\u002Fmin)",{"count":199,"type":22},28,[80],"The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.",[203,204],"AVP Deficiency","Diabetes Insipidus",[206,207,208],"Oxytocin","estradiol valerate","ethinylestradiol","2026-08-06",{"date":150,"type":34},{"date":212,"type":34},"2026-01-09",{"date":214,"type":22},"2027-02",{"name":40,"class":41},{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":247},"100603719","axillary-radiotherapy-or-axillary-lymph-node-dissection-in-patients-with-clinically-node--positive-breast-cancer-undergoing-upfront-tailored-axillary-surgery-100603719","NCT07140172","Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery","Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery: An International, Randomized Superiority Trial (OPBC-10\u002F NOAX)","OPBC-10\u002F NOAX","Inclusion Criteria at screening:\n\n* Written informed consent according to ICH\u002FGCP regulations prior to any trial specific procedures.\n* Patients ≥ 18 years of age.\n* Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) American Joint Committee on Cancer\u002F International Union Against Cancer (AJCC\u002FUICC) stage II-III (all molecular subtypes allowed).\n* Node-positivity detected by imaging and non-palpable (iN+) and confirmed by pathology.\n* Node-positivity palpable (cN1-3) and confirmed by pathology.\n* Occult breast cancer is allowed, if biopsy-proven axillary lymphatic metastasis is present.\n* Eligible for primary ALND or SLN procedure and either:\n\n  * Newly diagnosed.\n  * Isolated in-breast recurrence or second ipsilateral breast cancer after previous breast conserving surgery and sentinel procedure and at least 3 years disease free and no prior axillary dissection or axillary RT.\n* Upfront surgery setting.\n* Most suspicious axillary lymph node clipped. (If clipping is not part of the routine, this should be done after consent of the patient as a study procedure.)\n* Ability to complete the QoL questionnaires.\n* WHO performance status 0-2\n* Adequate condition for general anesthesia, breast cancer surgery and radiotherapy.\n* Adult patients (≥18 years of age).\n* Women of child-bearing potential are using effective contraception (condom, diaphragm, intrauterine device), are not pregnant or lactating and agree not to become pregnant during trial treatment (until end of RT) and thereafter during the time recommended by the guidelines - also for adjuvant systemic therapies. A negative pregnancy test before registration is required for all women of child-bearing potential.\n* Men agree not to father a child during trial treatment and for 6 months afterward.\n\nExclusion criteria at screening:\n\n* Stage IV breast cancer.\n* Clinical N3c breast cancer without axillary disease (clinical N3a and clinical N3b are allowed).\n* Clinical N2b breast cancer (clinical N2a is allowed).\n* Contralateral breast cancer within 3 years.\n* Prior axillary surgery (except prior sentinel node procedure in case of in-breast recurrence).\n* Prior regional radiotherapy.\n* Neoadjuvant treatment with the exception of bridging therapy given for less than 3 months.\n* History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from pre-registration with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer.\n* Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.\n\nExclusion criteria at randomization (intraoperatively):\n\n* Absence of clip in the specimen radiography.\n* Palpable disease left behind in the axilla after TAS.\n* No SLN identified in the axilla.",{"count":225,"type":22},1060,[80],"This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of lymphedema two years after randomization.",[229],"Breast Cancer",[231,232,233,234,235,236,237,238,239,240],"axillary lymph node dissection (ALND)","axillary radiotherapy (ART)","tailored axillary surgery (TAS)","clinically node positive breast cancer (cN+ BC)","sentinel lymph node biopsy (SLNB)","Breast cancer-specific survival (BCSS)","NOAX","OPBC-10","Lymphedema","Quality of life (QoL)",{"date":183,"type":34},{"date":243,"type":34},"2026-01-01",{"date":245,"type":22},"2037-12",{"name":40,"class":41},54,{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":256,"minAge":19,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":259,"conditions":260,"keywords":263,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":42},"100650064","oxytocin-in-postmenopausal-women-100650064","NCT07742124","Oxytocin in Postmenopausal Women","Circulating Oxytocin and Its Clinical Correlates in Postmenopausal Women Compared With Premenopausal Controls - The OxyMENO Study","OxyMENO","Inclusion Criteria:\n\n* Female sex at birth\n* Age ≥18 years\n\nPremenopausal group:\n\n• Premenopausal women aged 18-35 years with regular menstrual cycles (21-35 days) for ≥3 months prior to study entry\n\nPostmenopausal group:\n\n• Postmenopausal women ≥2 years of postmenopause (i.e. 3 years since last menstrual period (LMP), with menopause defined as ≥ 12 months of amenorrhea)\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Use of hormonal contraception or hormone replacement therapy within the last 3 months\n* Known endocrine disorders affecting the hypothalamic-pituitary-gonadal axis\n* Use of medications\n* Severe depression (BDI score \\> 28 points), any other severe psychiatric illness or acute medical disease\n* Inability to comply with study procedures\n* Participation in a trial with investigational drugs within the last 30 days","FEMALE",{"count":258,"type":22},30,"The aim of the present study is to assess whether cumulative endogenous neurophysin I secretion over one month differs between premenopausal and postmenopausal women. Using repeated measurements of neurophysin-I (NP-I, equimolar surrogate marker of oxytocin) across defined physiological time points, this study investigates oxytocin system regulation under cyclic and non-cyclic hormonal conditions.\n\nThe primary hypothesis is that cumulative NP-I release, expressed as the area under the curve (AUC) is lower in the postmenopausal group compared to the premenopausal group.",[261,262],"Postmenopausal","Premenopausal",[206,261,262,264,265,266],"Neurophysin-I","cyclic hormonal condition","menstrual cyclic phase","2026-07-31",{"date":269,"type":34},"2026-08-03",{"date":271,"type":22},"2027-06-01",{"date":273,"type":22},"2027-09-01",{"name":40,"class":41},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":299,"leadSponsor":301,"locationsCount":42},"100649744","a-comparative-usability-study-of-two-total-body-skin-imaging-systems-100649744","NCT07740642","A Comparative Usability Study of Two Total Body Skin Imaging Systems","A Comparative Usability Study of Two Total Body Skin Imaging Systems: Vectra (3D Total Body Photography With Manual Dermoscopy) Versus Deviskan (Total Body Photography With Automated Non-Contact Dermoscopy)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Signed informed consent by the participant\n* Sufficient proficiency in German\n* At least one of the following risk criteria for melanoma:\n\n  * Previous melanoma (including in situ)\n  * Suspected melanoma\n  * ≥ 100 common naevi\n  * ≥ 5 dysplastic naevi\n  * dysplastic naevus syndrome\n  * Known CDKN2A mutation\n  * Strong family history for melanoma (≥ first- and\u002For second-degree relatives)\n\nExclusion Criteria:\n\n* Lack of informed consent\n* Immobility. (Patients must be able to stand without support for 30 minutes.)\n* Inability to follow the procedures of the investigation, including inability to follow on-screen instructions or to read (e.g. due to visual impairment or cognitive impairment)\n* Vulnerable Subjects\n* Active skin conditions that may impact the performance of TBP systems or skin cancer screenings\n* Cardiac pacemaker\n* Pregnant women (self reported, no pregnancy test planned)\n* Height below 150 cm or above 195 cm\n* Severe Claustrophobia",{"count":283,"type":22},60,[80],"This study aims to generate evidence on patient and dermatologist perspectives regarding two total body photography systems. Patient and clinician preferences represent key factors in healthcare decision-making. The investigation will also provide data on the time efficiency of each system in a real-world setting.",[287],"Melanoma (Skin Cancer)",[289,290,291,292,293,294,295,296],"Screening","Body Photography","Total Body Photography","Dermoscopic Imaging Device","dermoscopy","Body skin imaging","Dysplastic Naevi","CDKN2A Mutation",{"date":269,"type":34},{"date":269,"type":22},{"date":300,"type":22},"2026-09-30",{"name":40,"class":41},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":327},"100650315","redo-pulmonary-vein-isolation-with-versus-without-posterior-wall-ablation---the-redo-pifpaf-pfa-study-100650315","NCT07745543","Redo-Pulmonary Vein Isolation With Versus Without Posterior Wall Ablation - The REDO-PIFPAF-PFA Study","Redo-Pulmonary Vein Isolation Using Pulsed-Field Ablation With Versus Without Posterior Wall Ablation in Patients With Symptomatic Atrial Fibrillation: A Multi-Centre Randomized Clinical Trial: The REDO-PIFPAF-PFA Study","Inclusion Criteria:\n\n1. Documented recurrence of paroxysmal or persistent AF following single prior catheter ablation with PVI, confirmed by 12-lead ECG, Holter monitoring, or ICM within the last 2 years.\n2. Candidate for repeat catheter ablation according to current European Society of Cardiology (ESC) AF management guidelines.\n3. Continuous oral anticoagulation with a vitamin K antagonist or non-vitamin K oral anticoagulant (NOAC) for ≥ 4 weeks prior to the ablation, or transoesophageal echocardiography (TEE) and\u002For cardiac computed tomography (CT) within 48 hours before the procedure excluding LA thrombus.\n4. Age ≥ 18 years at the time of informed consent.\n5. Written informed consent obtained prior to any study-related procedures.\n\nExclusion Criteria:\n\n1. Previous LA surgery\n2. \\> 1 prior LA ablation\n3. LA ablation outside of the PVs in the first LA ablation\n4. LA diameter \\>60 mm in the parasternal long axis\n5. Patients in persistent AF lasting \\>3 years\n6. AF due to reversible causes (e.g. hyperthyroidism, cardiothoracic surgery)\n7. Pre-existing PV stenosis or PV stent\n8. Pre-existing hemidiaphragmatic paralysis\n9. Contraindication to anticoagulation or radiocontrast materials\n10. Prior mitral valve surgery\n11. Severe mitral regurgitation or moderate\u002Fsevere mitral stenosis\n12. Myocardial infarction during the 3-month period preceding the consent date\n13. Ongoing triple antithrombotic\u002Fanticoagulation therapy\n14. Cardiac surgery during the 3-month interval preceding the informed consent date or scheduled cardiac surgery\u002Ftranscatheter aortic valve implantation procedure\n15. Significant congenital heart defect (including atrial septal defects or PV abnormalities but not including a patent foramen ovale)\n16. New York Heart Association (NYHA) class III or IV congestive heart failure\n17. Left ventricular ejection fraction (LVEF) \\\u003C35%\n18. Hypertrophic cardiomyopathy or left septal wall thickness \\>1.5 cm\n19. Significant chronic kidney disease (eGFR \\\u003C30 ml\u002Fmin)\n20. Uncontrolled hyperthyroidism\n21. Cerebral ischemic event (stroke or TIA) during the 6-month interval preceding the informed consent date\n22. Ongoing systemic infections\n23. Cardiac amyloidosis\n24. Pregnancy (to exclude pregnancy a blood test (HCG) is performed in women \\\u003C 50 years before inclusion)\n25. Life expectancy less than one year per physician opinion\n26. Currently participating in any other clinical trial, which may confound the results of this trial.\n27. Unwilling or unable to comply fully with the study procedures and FU.",{"count":310,"type":22},270,[80],"The study will compare two ablation strategies in patients with paroxysmal or persistent atrial fibrillation undergoing repeat ablation using pulsed-field ablation: redo pulmonary vein isolation only versus redo pulmonary vein isolation with added posterior wall ablation.",[314],"Atrial Fibrillation (AF)",[316,317,318],"Pulmonary vein isolation","Pulsed field albation","posterior wall ablation","2026-07-29",{"date":321,"type":34},"2026-08-04",{"date":323,"type":22},"2026-08",{"date":325,"type":22},"2031-07",{"name":40,"class":41},5,{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":345,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":42},"100650133","comparing-suture-vs-combined-closure-strategies-for-large-blood-vessel-access-in-patients-undergoing-transcatheter-aortic-valve-implantation-tavi-100650133","NCT07743697","Comparing Suture vs. Combined Closure Strategies for Large Blood Vessel Access in Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI)","SEAL-TAVI - Suture vs combinEd Closure strAtegies in Large-bore Access After TAVI","SEAL-TAVI","Inclusion Criteria:\n\n* Patient is at least 18 years of age at the time of screening.\n* Patient is scheduled to undergo elective transcatheter aortic valve implantation (TAVI) via transfemoral arterial access.\n* Patient is deemed suitable for transfemoral TAVI and large-bore vascular access closure by the local Heart Team.\n* Patient (or legally authorized representative) provides written informed consent prior to initiating any study-related procedures.\n* Patient is willing and able to comply with all specified study procedures, follow-up visits, and clinical evaluations.\n\nExclusion Criteria:\n\n* Planned TAVI procedure via non-femoral arterial access (e.g., transapical, transaortic, subclavian\u002Faxillary, or carotid access).\n* Emergency or non-elective TAVI procedure.\n* Target main femoral artery vessel diameter, calcification, or tortuosity judged unsuitable for standard percutaneous large-bore vascular closure device deployment.\n* Known active, unresolved local or systemic infection at the planned vascular access site.\n* Known severe allergy or hypersensitivity to bovine tissue, collagen, or any component of the study closure devices (Perclose ProGlide\u002FProStyle or Angio-Seal) that cannot be adequately premedicated.\n* Severe bleeding diathesis, active major bleeding, or absolute contraindication to standard periprocedural anticoagulation or antiplatelet therapy.\n* Concurrent participation in another interventional clinical trial investigating cardiovascular devices or drugs that could confound study endpoints.\n* Patient is pregnant or breastfeeding.\n* Patient belongs to a vulnerable population (e.g., individuals deprived of liberty, under guardianship, or unable to give informed consent).",{"count":337,"type":22},705,[80],"The goal of this clinical trial is to compare two strategies for closing the main artery access site in adult patients undergoing transcatheter aortic valve implantation (TAVI) through a blood vessel in the leg (transfemoral access).\n\nThe main questions it aims to answer are:\n\nDoes using a single suture device lower the rate of access-related vascular complications compared to using a hybrid combination of a suture device and a plug-based closure device? How do the two closure strategies compare regarding bleeding complications, procedure time, and time to complete vessel sealing?\n\nResearchers will compare a single-suture closure strategy to a hybrid closure strategy (one suture plus one plug-based device) to see if using a single suture reduces vessel-related complications and improves patient safety after TAVI.\n\nParticipants will:\n\nUndergo standard pre-procedure screening and TAVI via the main artery in the leg as part of routine medical care.\n\nReceive an initial single-suture placement before the large TAVI delivery system is inserted.\n\nBe evaluated after sheath removal for initial bleeding control; qualifying participants will then be randomly assigned (1:1) to either receive no additional device (single suture group) or receive a plug-based closure device (hybrid group).\n\nHave their heart and access site monitored during hospitalization, including laboratory checks and imaging prior to discharge.\n\nComplete a 72-hour safety and complication evaluation.",[341,342,343,344],"Aortic Valve Stenosis","Postoperative Complications","Vascular System Injuries","Hemorrhage",[334,346,347,348,349,350,351,352,353,354,355,356],"Transcatheter Aortic Valve Implantation","TAVI","Vascular Closure Device","Suture-Based Closure","Angio-Seal","ProGlide","ProStyle","Large-Bore Access","Vascular Complications","TAVR","Transcatheter Aortic Valve Replacement",{"date":321,"type":34},{"date":359,"type":22},"2026-10-01",{"date":361,"type":22},"2028-09",{"name":40,"class":41},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":105,"sex":18,"minAge":19,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":378,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":42},"100624391","sensory-stimulation-as-a-driver-of-diet-induced-thermogenesis-100624391","NCT07409025","Sensory Stimulation as a Driver of Diet-induced Thermogenesis","SEnsory stimulatioN aS A Driver of dieT-induced Thermogenesis - the SENSATION Trial","SENSATION","Inclusion Criteria:\n\n* healthy volunteers of any gender\n* BMI between 18-25 kg\u002Fm2\n* age between 18 and 40 years\n\nExclusion Criteria:\n\n* concomitant medication except for prescription free analgetics (paracetamol, NSAIDs) and oral contraceptives\n* clinically significant concomitant disease states (e.g. renal failure, hepatic dysfunction, cardiovascular disease, diabetes mellitus),\n* allergy to local anaesthetic or any of the study meal ingredients\n* known or suspected non-compliance, drug or alcohol abuse\n* smoker \u002F habitual tobacco use\n* habitual excessive alcohol consumption\n* inability to follow the procedures of the study\n* participation in another study with investigational drug within the 30 days preceding and during the present study\n* previous enrolment into the current study\n* enrolment of the investigator, his\u002Fher family members, employees and other dependent persons\n* uncontrolled hypo- or hyperthyroidism\n* pregnancy or lactation","40 Years",{"count":78,"type":22},[80],"This study aims to assess the influence of sensory stimulation on diet-induced energy expenditure by way of a clinical cross-over trial in 24 healthy participants either receiving a meal bolus with (orally) and without sensory stimulation (nasogastric-tube).",[376,377],"Diet-induced Thermogenesis","Sensory Function",[379,380],"Diet-induced thermogenesis","Sensory Stimulation","2026-07-28",{"date":383,"type":34},"2026-07-30",{"date":385,"type":34},"2026-07-27",{"date":387,"type":22},"2028-01",{"name":40,"class":41},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":415},"100649144","early-detection-and-intervention-in-heart-failure-100649144","NCT07731490","Early Detection and IntervenTion in Heart Failure","EDIT-HF","Inclusion Criteria:\n\n* General consent (GC) has not been rejected.\n* Age ≥ 65 years.\n* Elective percutaneous coronary intervention\\* (PCI), pulmonary vein isolation\\* (PVI), pacemaker implantation\\* (PM, no cardiac resynchronisation), transcatheter aortic valve intervention\\* (TAVI), major non-cardiac surgery\\* or presenting with tachyarrhythmia to the emergency department (ED) (without a diagnosis of HF within 24h).\n\n  * Exclusion criteria are assessed on day 1 after the procedure\n\nExclusion Criteria:\n\n* Systolic blood pressure ≤ 95 mmHg\n* Estimated glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2.\n* Dementia documented in the medical history.\n* Metastatic cancer in the medical history.\n* Previously enrolled in this study.\n* Known HF.\n* Known allergies, hypersensitivity, or intolerance to SGLT2 Inhibitors \u002F Loop Diuretics \u002F MRA or is excipients.\n* Non-resident in the country of the recruiting site\n* Incapacity of the patient to make judgements\n* Patients not hospitalized overnight\n* Patients requiring intensive care unit (ICU) or intermediate care (IMC) stay beyond 11:00 a.m. on the first postoperative day or any post-interventional stroke unit stay until 8:00 a.m. on the first postoperative day.\n* Patients died prior to postinterventional day 1 (8:00 a.m.)\n* Severe aortic or mitral stenosis",{"count":397,"type":22},18000,[80],"Heart failure (HF) occurs when the heart is no longer able to pump blood effectively throughout the body. This leads to symptoms that gradually worsen over time and are often mistaken for normal signs of aging. Because of its insidious onset, early detection is challenging. Both patients and healthcare professionals are often insufficiently aware of the early signs and symptoms of HF, resulting in delayed diagnosis. Consequently, timely initiation of treatments that could slow disease progression, improve quality of life, and reduce hospitalizations is often missed. Although a simple blood test measuring NT-proBNP levels can facilitate the early diagnosis of HF, it is not routinely used in clinical practice.\n\nThe aim of this study is to evaluate whether a combined strategy for the early diagnosis and treatment of HF can reduce hospitalizations. This strategy includes:\n\n1. increasing awareness of HF among patients and physicians,\n2. using NT-proBNP testing for the early detection of HF in high-risk patients, and\n3. promptly initiating guideline-directed HF treatment when the diagnosis is confirmed.\n\nThe researchers will assess whether this strategy effectively reduces hospitalizations due to acute heart failure over an 18-month follow-up period.",[401],"Heart Failure (HF)",[403,404,405,406,407],"NT-proBNP","Stepped-Wedge","Undetected Heart Failure","Heart Failure","Implementation Science","2026-07-24",{"date":381,"type":34},{"date":411,"type":34},"2025-12-03",{"date":413,"type":22},"2030-04",{"name":40,"class":41},21,{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":105,"sex":256,"minAge":19,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":42},"100624390","development-of-a-patient-centered-assessment-tool-for-pain-during-cesarean-delivery-100624390","NCT07409012","Development of a Patient-Centered Assessment Tool for Pain During Cesarean Delivery","Pain During Cesarean Delivery: a Patient-Centered Assessment Tool Developed With Mixed Methods","Inclusion Criteria:\n\n* Signed informed consent\n* Age \\> 18 years\n* Proficient in German or Swiss German\n* Category 2-4 Cesarean delivery under neuraxial anesthesia within last 48-72 hours\n* Delivery of an healthy infant of at least 35+1 weeks of gestation\n\nExclusion Criteria:\n\n* Known fetal abnormalities or neonatal death\n* Admission of the neonate to the ICU\n* Severe postpartum hemorrhage of \\>1000ml blood loss\n* Preeclampsia\n* Current psychiatric disease, e.g. schizophrenia, personality disorders\n* Substance abuse\n* Chronic pain disease",{"count":424,"type":22},12,"This study aims to develop a standardized tool to assess intraoperative pain during cesarean delivery under neuroaxial anesthesia. The tool will draw on existing scientific literature, expert clinical opinion and the experiences of patients who have recently undergone caesarean delivery. Experts from multiple disciplines will participate in a structured consensus process (Delphi process) to identify and refine key assessment items. Patient interviews will be conducted to ensure that the tool reflects patient priorities and experiences.",[427],"Elective Cesarean Delivery","2026-07-23",{"date":408,"type":34},{"date":431,"type":34},"2026-05-11",{"date":433,"type":22},"2026-09",{"name":40,"class":41},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":454,"locationsCount":42},"100544317","extraperitoneal-plasty-vs-intraperitoneal-onlay-mesh-in-ventral-hernia-repair-100544317","NCT06367309","ExtrAperitoneaL Plasty vs Intraperitoneal oNlay mEsh in Ventral Hernia Repair","ExtrAperitoneaL Plasty vs Intraperitoneal oNlay mEsh in Ventral Hernia Repair - the Randomized Controlled ALPINE Trial","ALPINE","Inclusion Criteria:\n\n* Patient age \\>18 years\n* Informed consent obtained\n* Primary or incisional ventral hernia\n* Epigastric, umbilical or infraumbilical ventral hernias with transversal diameter \\>1cm and \\\u003C\u002F= 4cm, +\u002F- rectus diastasis which doesn't demand specific treatment\n* If multiple hernias: cumulative transversal diameter \\\u003C\u002F= 4cm\n* Considered eligible for minimally-invasive approach\n\nExclusion Criteria:\n\n* Subxyphoidal or suprapubic hernias\n* precedent hernia treatment with mesh placement in the retromuscular space\n* liver disease defined by the presence of ascites\n* end-stage renal disease requiring dialysis\n* need of an emergency surgery\n* pregnancy\n* need of rectus diastasis treatment intraoperatively\n\nCriteria for participating surgeons\n\n\\- Each participating surgeon has performed 20 or more laparoscopic IPOM procedures and 20 or more eTEP procedures.",{"count":444,"type":22},138,[80],"This study investigates on the effect of two different operative techniques to treat abdominal wall hernias.\n\nThe goal of this clinical trial is to learn if the eTEP (Extended totally extraperitoneal repair) technique leads to a better outcome than the IPOM (Intraperitoneal onlay mesh) technique.\n\nThe main questions it aims to answer are:\n\n* pain after the operation\n* rate of complications\n* rate of recurrence and reoperations\n* quality of life.\n\nParticipants will:\n\nEither be operated using the eTEP or the IPOM technique. Be followed up either in person or via email \u002F phone call at day 1, day 7, day 14, 6 weeks, 6 months, 1, 3 and 5 years after the surgery to asses the above-stated main and some more outcomes.",[448,449],"Ventral Hernia","Abdominal Wall Defect",{"date":408,"type":34},{"date":64,"type":34},{"date":453,"type":22},"2031-12-31",{"name":40,"class":41},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":465,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":475},"100544086","open-versus-robotic-retromuscular-repair-in-medium-to-large-ventral-hernias-100544086","NCT06364306","oPen Versus RobotIc retrOmuscular Repair in Medium to Large Ventral Hernias","oPen Versus RobotIc retrOmuscular Repair in Medium to Large Ventral Hernias - the PRIOR Multicentre Randomized Controlled Trial","PRIOR","Inclusion Criteria:\n\n* Patient age \\>18 years\n* Informed consent obtained\n* Transverse diameter of ventral hernia \\>4cm - 15cm\n* Eligible to open and minimally-invasive surgery according to preoperative anaesthetic assessment\n\nExclusion Criteria:\n\n* precedent hernia treatment with mesh placement in the retromuscular space\n* precedent anterior or posterior component separation or transversus abdominis release (TAR)\n* active wound infection\n* current cancer diagnosis\n* presence of ileostomy, colostomy or ileal conduit\n* liver disease defined by the presence of ascites\n* end-stage renal disease requiring dialysis\n* need of an emergency surgery\n* pregnancy\n\nCriteria for participating surgeons Each participating surgeon has performed 20 or more OVHR and RVHR.",{"count":464,"type":22},140,[80],"This study investigates on the effect of two different operative techniques to treat large abdominal wall defects.\n\nThe goal of this clinical trial is to learn if the minimally-invasive, robotically-assisted ventral hernia repair (RVHR) leads to a better outcome than the open ventral hernia repair (OVHR).\n\nThe main questions it aims to answer are:\n\nlength of stay after the operation rate of complications rate of recurrence and reoperations quality of life.\n\nParticipants will:\n\nEither be operated using the RVHR or OVHR will be followed up either in person or via email \u002F phone call at day 7, day 30, 6 months, 1, 3 and 5 years after the surgery to asses the above-stated main and some more outcomes.",[448,468,449],"Incisional Hernia",{"date":408,"type":34},{"date":471,"type":34},"2026-07-14",{"date":473,"type":22},"2033-12-31",{"name":40,"class":41},3,{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":490,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":424},"100589778","linezolid-plus-standard-of-care-100589778","NCT06958835","Linezolid Plus Standard of Care","Combination Antibiotic Treatment With Linezolid for Staphylococcus Aureus Bacteraemia: a Randomised Controlled Trial","LIPS","Inclusion criteria:\n\n* Staphylococcus aureus (S. aureus) grown from at least one blood culture\n* Hospitalised at a participating centre\n* ≥18 years old\n* Written informed consent or fulfilling criteria for an emergency exception from informed consent requirements\n\nExclusion criteria:\n\n* Administration of the initial drug treatment not feasible within 72 hours since the collection of the first positive blood culture with S. aureus\n* Documented history of positive blood cultures for S. aureus occurring between 72 hours and 180 days prior to the eligibility assessment\n* Necrotising fasciitis\n* Currently receiving linezolid or clindamycin\n* Use of any monoamine oxidase A or B inhibitor within the last two weeks\n* Known hypersensitivity to linezolid or any other ingredients of the study drugs\n* Current severe thrombocytopenia (i.e. \\\u003C30 x 10\\^9\u002FL)\n* Application of study drug not possible (per mouth or per gastric tube)\n* Currently breastfeeding\n* Local treating team believes that death is imminent and inevitable\n* Patient is receiving end of life care and antibiotic treatment is not considered appropriate\n* Local treating team believes that participation in the study is not in the best interest of the patient\n* Any indication that the patient is unwilling to participate in the study including an advance directive stating such unwillingness",{"count":485,"type":22},606,[80],"The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.",[489],"Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)",[491,492,493,494,495,496,497,498,499,500],"Virulence factors","Linezolid","Bloodstream Infection","Hierarchical composite endpoint","Staphylococcus aureus","Bacteremia","Bacteraemia","Methicillin-resistant Staphylococcus aureus (MRSA)","Penicillin-susceptible Staphylococcus aureus (PSSA)","Methicillin-susceptible Staphylococcus aureus (MSSA)","2026-07-09",{"date":503,"type":34},"2026-07-13",{"date":505,"type":34},"2025-10-06",{"date":507,"type":22},"2028-10",{"name":40,"class":41},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":518,"conditions":519,"keywords":522,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":42},"100646045","feasibility-study-continuous-ecg-and-blood-pressure-monitoring-with-the-m2vs-sensor-system-100646045","NCT07694570","Feasibility Study: Continuous ECG and Blood Pressure Monitoring With the M2VS Sensor System","Feasibility Study for Continuous Monitoring of Electrocardiogram (ECG) and Blood Pressure at the Chest and Upper Arm Using the M2VS System.","Inclusion Criteria:\n\n* Written informed consent obtained prior to any project-specific procedures.\n* Age 18 years or older at the time of enrolment.\n* Ability to provide valid informed consent.\n* Clinical indication for 24-hour Holter monitoring (Holter cohort) or 24-hour ABPM (ABPM cohort).\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language, preventing adequate understanding of the project procedures and informed consent.\n* Enrolment of the project leader, project staff, their family members, employees, or other dependent persons.\n\nDermatological and Sensor Placement:\n\n* Pre-existing skin conditions at the application sites (medial upper arm or chest), such as extensive scarring, tattoos, open wounds, active inflammation, or severe oedema that could interfere with sensor coupling or signal quality.\n* Excessive hair at the application site that could interfere with sensor coupling or signal quality.\n* Presence of other concurrent wearable devices at the same anatomical application site that could interfere with the M2VS system.\n* Known allergy to skin-contacting materials utilized in the M2VS system.",{"count":517,"type":22},20,"In this study, the investigators want to find out whether a new wearable sensor system, called the M2VS system, can reliably measure heart activity, blood pressure, and other vital signs over 24 hours during normal daily life.\n\nThe investigators also want to compare the M2VS system with the standard devices currently used for long-term heart and blood pressure monitoring, such as a Holter ECG and an ambulatory blood pressure monitor (ABPM). This will provide an estimation of the accuracy of the M2VS system's ECG and blood pressure measurements compared to the standard devices.\n\nThe aim of the study is to assess how reliable the M2VS system is in terms of data completeness and how comfortable it is to wear compared with the usual monitoring devices.\n\nIn the future, the results of this study may help make the monitoring of heart and blood vessel diseases more comfortable and easier for patients.",[520,521],"Atrial Fibrillation (Paroxysmal)","Hypertension",[523,524,525,526],"Feasibilty Study","M2VS system","ECG","Electrocardiogram","2026-07-03",{"date":529,"type":34},"2026-07-10",{"date":531,"type":22},"2026-07-01",{"date":533,"type":22},"2026-08-31",{"name":40,"class":41},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":18,"minAge":543,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":546,"conditions":547,"keywords":550,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":475},"100575574","swiss-prospective-cohort-of-transgender-and-gender-diverse-individuals---the-spectra-study-100575574","NCT06774053","Swiss ProspectivE Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study","Swiss Prospective Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study","SPECTRA","Inclusion Criteria:\n\n* Age 16 years and above.\n* Established diagnosis of gender incongruence\n* Indication for gender affirming therapy or ongoing or discontinued gender affirming therapy\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Missing commitment or ability to study protocol adherence","16 Years",{"count":545,"type":22},600,"The goal of this observational study is to understand the factors influencing the well-being and health of transgender and gender-diverse (TGD) individuals undergoing gender-affirming therapies in Switzerland. The study population includes TGD individuals aged 16 and older, at various stages of their medical transition, including those who have discontinued or detransitioned.\n\nThe main question is:\n\nWhat are the key factors influencing the well-being and health outcomes of transgender and gender-diverse individuals undergoing gender-affirming therapies?\n\nResearchers will compare health outcomes across different subgroups, such as those at different stages of transition or detransition, to examine the effects of gender-affirming therapies.\n\nParticipants will:\n\nComplete electronic questionnaires assessing gender congruence, quality of life, mental health, and other outcomes.\n\nProvide biological samples (e.g., blood, urine, stool, and skin swabs) for laboratory analysis.\n\nUndergo clinical evaluations related to endocrinology, fertility, dermatology, and urology as part of their routine follow-up.",[548,549],"Transgender Individuals","Gender Incongruence",[551,552,553],"Gender Affirming Hormone Therapy (GAHT)","Gender Affirming Surgery (GAS)","Transgender and Gender Diverse (TGD)",{"date":555,"type":34},"2026-06-30",{"date":557,"type":34},"2026-04-20",{"date":559,"type":22},"2046-01",{"name":40,"class":41},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":76,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":571,"conditions":572,"keywords":576,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":595},"100485045","impact-of-personalised-cardiac-anaesthesia-and-cerebral-autoregulation-on-neurological-outcomes-in-patients-undergoing-cardiac-surgery-100485045","NCT05595954","Impact of Personalised Cardiac Anaesthesia and Cerebral Autoregulation on Neurological Outcomes in Patients Undergoing Cardiac Surgery","Impact of Personalised Cardiac Anaesthesia and Cerebral Autoregulation on Neurological Outcomes in Patients Undergoing Cardiac Surgery (PRECISION)","PRECISION","Inclusion Criteria:\n\n* Elective primary or reoperative coronary artery bypass graft and\u002For valvular and\u002For ascending aorta surgery requiring cardiopulmonary bypass.\n\nExclusion Criteria:\n\n* Surgery requiring moderate (28-31.9ºC) or deep (\\\u003C28ºC) hypothermic circulatory arrest;\n* Heart and\u002For lung transplantation;\n* Urgent (within 24 hours) and emergency surgery;\n* Inability to follow procedures or insufficient knowledge in English, German or French;\n* Inability to give consent.\n\nParticipants who undergo cardiac surgery under minimal extracorporeal circulation will also be excluded.",{"count":570,"type":22},500,"This international, multicentre prospective cohort study will assess whether perioperative duration and magnitude of mean arterial pressure (MAP) outside of an individual's cerebral autoregulation (CA) limits using near-infrared spectroscopy (NIRS) and transcranial Doppler (TCD) are associated with adverse neurological events. It is to investigate whether patients with a higher burden of cerebral haemodynamic insults have an increased incidence or poorer neurological outcomes. Associations between neurologic outcomes, neurobiomarkers and genetic tests will be explored.",[573,574,575],"Postoperative Delirium","Postoperative Stroke","Postoperative Cognitive Dysfunction",[577,578,579,580,581,582,583,584,585,586,587],"cerebral autoregulation","hypotension","neurological outcomes","adverse neurological events","postoperative delirium","postoperative stroke","postoperative cognitive decline","personalised cardiac anaesthesia","cardiac surgery","near-infrared spectroscopy","transcranial Doppler","2026-06-25",{"date":555,"type":34},{"date":591,"type":34},"2023-01-23",{"date":593,"type":22},"2027-06",{"name":40,"class":41},4,{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":23,"phases":605,"briefSummary":606,"conditions":607,"keywords":610,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":42},"100636759","copeptin-measurement-after-mannitol-and-hypertonic-saline-for-the-diagnosis-of-polyuria-polydipsia-syndrome-100636759","NCT07569861","Copeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia Syndrome","COMPASS","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Hypotonic polyuria\u002Fpolydipsia syndrome defined as polyuria \\>40ml\u002Fkg body weight\u002F24h and polydipsia \\>3l\u002F24h; and urine osmolality \\\u003C800mOsm\u002FL or known AVP-D based on accepted criteria\n\nExclusion Criteria:\n\n1. Polyuria\u002Fpolydipsia secondary to diabetes mellitus, hypercalcemia, or hypokalemia\n2. Diagnosis of AVP-R (Copeptin \\> 21.4 pmol\u002FL)\n3. Evidence of acute illness\n4. Epilepsy requiring treatment\n5. Uncontrolled arterial hypertension (blood pressure \\>160\u002F100mmHg at baseline\n6. eGFR \\\u003C 60 ml\u002Fmin\u002F1,73 m2\n7. Cardiac failure (NYHA III-IV)\n8. Diagnosis of liver cirrhosis, Child-Pugh Class C\n9. Uncorrected adrenal or thyroidal deficiency\n10. Pregnancy or breastfeeding\n11. Current or unresolved urinary obstruction\n12. Enrollment in a clinical trial within the last 30 days\n13. Patients refusing or unable to give written informed consent\n14. Inability to follow study procedures",{"count":604,"type":22},144,[80],"The aim of this study is to evaluate whether a new test using mannitol infusion can diagnose the cause of polyuria-polydipsia syndrome as accurately as the current standard test (hypertonic saline infusion) and to compare which test patients prefer. The goal is to identify a simpler and more patient-friendly diagnostic approach.",[608,609],"Arginine Vasopressin Deficiency","Primary Polydipsia",[611,612,613,614],"Copeptin Measurement","Diagnosis of Polyuria-polydipsia syndrome","Mannitol","Hypertonic Saline Infusion","2026-06-17",{"date":617,"type":34},"2026-06-18",{"date":619,"type":34},"2026-06-16",{"date":621,"type":22},"2030-06",{"name":40,"class":41},{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":629,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":631,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":632,"conditions":633,"keywords":636,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":646},"100537603","pupillometric-evaluation-in-patients-declared-brain-dead---a-prospective-quality-control-study-100537603","NCT06279975","Pupillometric Evaluation in Patients Declared Brain Dead - a Prospective Quality Control Study","Investigative Neurological Study With Pupillometric Evaluation os a Clinical Tool in Patients Declared Brain Dead (INSPECT) - a Prospective Quality Control Study","INSPECT","Inclusion Criteria:\n\n* Suspected diagnosis of brain death\n* Brain death diagnostic procedures planned\n* Treated at the intensive care unit at the University Hospital Basel (USB)",{"count":165,"type":22},"The aim of the study is to verify the reliability of the current purely clinical examination of the pupils (without the support of a pupillometer) in the context of clinically suspected brain death, compared to the results of a non-invasive, automated, and highly precise monocular pupillometric examination.",[634,635],"Brain Death","Adults",[637,634,638],"Pupillometry","Diagnosis","2026-06-15",{"date":615,"type":34},{"date":642,"type":34},"2023-12-18",{"date":644,"type":22},"2030-12",{"name":40,"class":41},2,{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":655,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":657,"conditions":658,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":660,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":42},"100426171","firm-observational-clinical-unicenter-study-on-guillain-barr-syndrome-100426171","NCT04829526","Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome","Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome (FOCUS on GBS)","FOCUS on GBS","Inclusion Criteria:\n\n* suspected diagnosis of GBS, who have been treated at the University Hospital of Basel from 01.01.2005-28.02.2021\n\nExclusion Criteria:\n\n* Patients with documented refusal of the general consent.",{"count":656,"type":22},100,"The aim of this retrospective observational single-center cohort study is to gain a deeper understanding regarding the frequency, the clinical and electrophysiologic characteristics (e.g., the diagnostic work up), complications, treatment regimes, and their associations with specific courses of disease and outcomes in adult patients with the suspected or proven diagnosis of GBS.",[659],"Guillain-Barre Syndrome (GBS)",{"date":615,"type":34},{"date":662,"type":34},"2021-03-01",{"date":664,"type":22},"2026-07",{"name":40,"class":41},{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":672,"eligibilityCriteria":673,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":674,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":676,"conditions":677,"keywords":679,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":683,"startDateStruct":684,"completionDateStruct":686,"leadSponsor":688,"locationsCount":646},"100389241","advance-directive-implementation-and-scientific-evaluation-study-100389241","NCT04348318","Advance Directive Implementation and Scientific Evaluation Study","Advance Directive Implementation and Scientific Evaluation (ADVISE) Study","ADVISE","Inclusion Criteria:\n\n* adult patients treated for more than 48 hours in the intensive care unit (post-operative or internal medicine) of the University Hospital Basel in the years 2011-2023\n\nExclusion Criteria:\n\n* Patients with documented refusal of the general consent.\n* Patients who have been treated in the intensive care unit for less than 48 hours",{"count":675,"type":22},2000,"This study is to better understand the use of advance directives, their implementation in the intensive care unit, and their effects on outcome. Data from the digital medical records of all consecutive adult patients admitted to the intensive care unit at the University Hospital Basel from 2011 to 2023 are retrospectively extracted. Descriptive analyses will be applied to report the proportion of patients with an advance directive. In-hospital outcome (defined as survival, Glasgow Outcome Score, and return of neurologic function to premorbid baseline) will be compared between patients with and without advanced directives",[678],"Loss of Capability of Judgement",[680,681,682],"advance directives","life-sustaining treatment","neurocritical illness",{"date":615,"type":34},{"date":685,"type":34},"2021-08-03",{"date":687,"type":22},"2050-12",{"name":40,"class":41},""]